Heartflow CFO Verghese sells over $1.2 million in company stock
HeartFlow CFO Vikram Verghese sold 24,345 shares worth $1.23M in two transactions, under a 10b5-1 plan, with shares trading near 52-week high. HeartFlow reported Q2 2026 revenue of $64.1M, up 48% YoY, and narrowed loss. Stifel raised its price target to $45, maintaining a Buy rating.
How this was made
The 30-second read
Why it matters
Insider sale adds a fresh data point that may temper the stock's momentum despite strong earnings.
Market read
Primary news is the CFO's insider sale; earnings data is recapped but not new.
What to watch
Recent earnings beat and raised price target may offset selling pressure.
Background
HeartFlow reported Q2 2026 revenue of $64.1M and a narrower loss than expected, prompting a price‑target raise.
Ticker impact
CFO Vikram Verghese sold 24,345 shares for $1.23M via a 10b5-1 plan, a new Form 4 filing.
modest short-term downside pressure
The sale represents a sizable insider divestiture shortly after a strong earnings beat, which could temper recent rally.
Market effects
Limited impact on the broader health‑tech sector; the sale is company‑specific.
No significant regional effect; the filing is U.S.‑listed.
Minimal global relevance beyond HTFL investors.
Counterpoint
The sale could be routine under a pre‑established plan, not a bearish signal.
Key entities
- companyHeartFlow, Inc.
Medical imaging company listed on NASDAQ (HTFL).
- executiveVikram Verghese
Chief Financial Officer of HeartFlow.
